This is an external website. DAIC is not responsible for any content on the third party website.
July 22, 2026 — Penumbra, Inc. recently announced the results of Thunder, an Investigational Device Exemption (IDE) ...
June 30, 2026 — Penumbra Inc. has received the CE Mark for Red 72 Silver Label and Red 72 Silver Label with SENDit ...
June 15, 2006 — Penumbra, Inc. has secured the CE Mark in Europe for Thunderbolt, further laying the groundwork for ...
June 11, 2026— Penumbra, Inc. has received U.S. Food and Drug Administration (FDA) clearance for Thunderbolt, expanding ...
Venous thromboembolism (VTE), and pulmonary embolism (PE) in particular, are among the most complex and dangerous acute ...
April 13, 2026 — Penumbra, Inc. announced 90-day results of the landmark STORM-PE randomized controlled trial (RCT) ...
Jan. 15, 2026 — Boston Scientific Corp. and Penumbra, Inc. have entered into a definitive agreement under which Boston ...
Dec. 16, 2025 — A new study, published in the American Journal of Cardiology, found that the use of Computer Assisted ...
Oct. 27, 2025 – Penumbra, Inc. has announced the results of the STORM-PE randomized controlled trial (RCT), which found ...
June 16, 2025 – Penumbra, Inc. recently announced the completion of enrollment in the STORM-PE clinical trial. This ...